Last $14.84 USD
Change Today 0.00 / 0.00%
Volume 0.0
ABSCF On Other Exchanges
EN Paris
As of 4:30 PM 06/24/14 All times are local (Market data is delayed by at least 15 minutes).

ab science sa (ABSCF) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/18/13 - $27.20
52 Week Low
06/24/14 - $14.84
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AB SCIENCE SA (ABSCF)

Related News

No related news articles were found.

ab science sa (ABSCF) Related Businessweek News

No Related Businessweek News Found

ab science sa (ABSCF) Details

AB Science S.A., a pharmaceutical company, engages in the research, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines in the United States and Europe. Its lead compound includes Masitinib, a tyrosine kinase inhibitor that targets mast cells and selected kinases, including c-Kit, PDGR, and Lyn. The company focuses on therapies for the treatment of cancer, inflammatory diseases, and central nervous system diseases. It is also pursuing eight on-going phase III studies in human medicine in GIST, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, mastocytosis, severe persistent asthma, rheumatoid arthritis, and progressive multiple sclerosis. The company markets its Masitinib under the Masivet brand name for the veterinary market in Europe. Its products are used by hospitals and specialist physicians. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.

99 Employees
Last Reported Date: 04/28/14
Founded in 2001

ab science sa (ABSCF) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: €387.1K
Compensation as of Fiscal Year 2012.

ab science sa (ABSCF) Key Developments

AB Science S.A., Annual General Meeting, Jun 24, 2014

AB Science S.A., Annual General Meeting, Jun 24, 2014.

AB Science SA Reports Earnings Results for the Year Ended December 31, 2013

AB Science SA reported earnings results for the year ended December 31, 2013. For the period, the company’s total revenues were EUR 1,933,000 against EUR 1,340,000 a year ago. Operating loss was EUR 13,772,000 against EUR 10,613,000 a year ago. Net loss was EUR 14,611,000 against EUR 10,985,000 a year ago. Net income for the period attributable to equity holders of the parent company was EUR 14 611,000 or EUR 0.45 per basic and diluted share against EUR 10,985,000 or EUR 0.34 per basic and diluted share a year ago. Net cash flow from operating activities was EUR 12,835,000 against EUR 6,211,000 a year ago.

AB Science S.A.(ENXTPA:AB) added to CAC Small Index

AB SCIENCE will be added to the CAC Small Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABSCF:US $14.84 USD 0.00

ABSCF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ABSCF.
View Industry Companies

Industry Analysis


Industry Average

Valuation ABSCF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 150.3x
Price/Book 840.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 120.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AB SCIENCE SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at